Awanish Pandey, VP, Research and Strategy at SPER Market Research, shared OncoDaily’s post on LinkedIn:
“Grateful to be part of Immuno 2026 and contribute to this global conversation on the future of cancer immunotherapy.
Thank you to OncoDaily and the Parker Institute for Cancer Immunotherapy for bringing together experts from around the world.
I was honored to share insights on ‘In Vivo CAR-T Therapy: Emerging Strategies, Challenges, and Future Perspectives.’ I’m also grateful to all the panelists for their valuable insights, thoughtful perspectives, and engaging discussions, which made the conversations truly enriching.
A valuable platform to exchange ideas on how next-generation immunotherapies can become more accessible and impactful for patients worldwide.”
You may also be interested in: Immuno 2026 Day 6 Highlights: Dose Optimization and Better Research Decisions
